» Articles » PMID: 9696861

Continued Utilization of CCR5 Coreceptor by a Newly Derived T-cell Line-adapted Isolate of Human Immunodeficiency Virus Type 1

Overview
Journal J Virol
Date 1998 Aug 8
PMID 9696861
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The differential use of CC chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) may be intimately involved in the transmission and progression of human immunodeficiency virus infection. Changes in coreceptor utilization have also been noted upon adaptation of primary isolates (PI) to growth in established T-cell lines. All of the T-cell line-adapted (TCLA) viruses studied to date utilize CXCR4 but not CCR5. This observation had been suggested as an explanation for the sensitivity of TCLA, but not PI, viruses to neutralization by recombinant gp120 antisera and V3-directed monoclonal antibodies, but recent studies have shown coreceptor utilization to be independent of neutralization sensitivity. Here we describe a newly isolated TCLA virus that is sensitive to neutralization but continues to utilize both CXCR4 and CCR5 for infection. This finding further divorces coreceptor specificity from neutralization sensitivity and from certain changes in cell tropism. That the TCLA virus can continue to utilize CCR5 despite the changes that occur upon adaptation and in the apparent absence of CCR5 expression in the FDA/H9 T-cell line suggests that the interaction between envelope protein and coreceptor may be mediated by multiple weak interactions along a diffuse surface.

Citing Articles

Characterization of SIV in the oral cavity and in vitro inhibition of SIV by rhesus macaque saliva.

Thomas J, Lacour N, Kozlowski P, Nelson S, Bagby G, Amedee A AIDS Res Hum Retroviruses. 2010; 26(8):901-11.

PMID: 20672998 PMC: 2957632. DOI: 10.1089/aid.2009.0235.


Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.

Shibata J, Yoshimura K, Honda A, Koito A, Murakami T, Matsushita S J Virol. 2007; 81(8):3757-68.

PMID: 17251298 PMC: 1866102. DOI: 10.1128/JVI.01544-06.


Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.

York J, Follis K, Trahey M, Nyambi P, Zolla-Pazner S, Nunberg J J Virol. 2001; 75(6):2741-52.

PMID: 11222697 PMC: 115898. DOI: 10.1128/JVI.75.6.2741-2752.2001.

References
1.
Groenink M, Fouchier R, de Goede R, de Wolf F, Gruters R, Cuypers H . Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J Virol. 1991; 65(4):1968-75. PMC: 240031. DOI: 10.1128/JVI.65.4.1968-1975.1991. View

2.
Lusso P, Cocchi F, Balotta C, Markham P, Louie A, Farci P . Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol. 1995; 69(6):3712-20. PMC: 189087. DOI: 10.1128/JVI.69.6.3712-3720.1995. View

3.
Schuitemaker H, Koot M, Kootstra N, Dercksen M, de Goede R, van Steenwijk R . Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol. 1992; 66(3):1354-60. PMC: 240857. DOI: 10.1128/JVI.66.3.1354-1360.1992. View

4.
Koot M, Vos A, Keet R, de Goede R, Dercksen M, Terpstra F . HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS. 1992; 6(1):49-54. DOI: 10.1097/00002030-199201000-00006. View

5.
Fouchier R, Groenink M, Kootstra N, Tersmette M, Huisman H, Miedema F . Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol. 1992; 66(5):3183-7. PMC: 241084. DOI: 10.1128/JVI.66.5.3183-3187.1992. View